Adherence of Stalevo, Entacapone and Levodopa
This study has been completed.
Sponsor:
South Glasgow University Hospitals NHS Trust
Information provided by:
South Glasgow University Hospitals NHS Trust
ClinicalTrials.gov Identifier:
NCT00245700
First received: October 27, 2005
Last updated: May 22, 2008
Last verified: May 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To test if combining two antiparkinson drugs into a single tablet improves accuracy of medicine intake by the patient.
To test if patients with Parkinson's disease who take medicines at regular time intervals have smoother symptom control.
| Condition |
|---|
|
Parkinson's Disease |
| Study Type: | Observational |
| Official Title: | Study of Adherence of Stalevo, Entacapone and Levodopa |
Resource links provided by NLM:
Further study details as provided by South Glasgow University Hospitals NHS Trust:
Eligibility| Ages Eligible for Study: | 18 Years to 85 Years (Adult, Senior) |
| Genders Eligible for Study: | Both |
Criteria
Inclusion Criteria:
- Patients diagnosed with Parkinson's disease aged between 18 and 85 years fulfilling UK Brain Bank criteria.
- Current levodopa therapy prescribed on a regular basis three or more times per day but requiring entacapone because of 'wearing off'
- Able to manipulate electronic monitoring bottles and complete questionnaires
Exclusion Criteria:
- Current use of compliance aid such that study participation would be detrimental to patient's adherence
- Pregnancy or breast feeding
- Excess alcohol (over 21 units per week for women and 28 units for men)
- Mini mental state examination of less than 26.
- Severe depression (Geriatric depression score over 20)
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00245700
Please refer to this study by its ClinicalTrials.gov identifier: NCT00245700
Locations
| United Kingdom | |
| Southern General Hospital | |
| Glasgow, Scotland, United Kingdom, G51 4TF | |
Sponsors and Collaborators
South Glasgow University Hospitals NHS Trust
Investigators
| Principal Investigator: | Donald G Grosset, MBChB, MD |
More Information
| Responsible Party: | Dr D Grosset, Southern General Hospital |
| ClinicalTrials.gov Identifier: | NCT00245700 History of Changes |
| Other Study ID Numbers: | R050017 Grant from Orion Pharma |
| Study First Received: | October 27, 2005 |
| Last Updated: | May 22, 2008 |
| Health Authority: | United Kingdom: Research Ethics Committee |
Additional relevant MeSH terms:
|
Parkinson Disease Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Movement Disorders Neurodegenerative Diseases Entacapone |
Levodopa Antiparkinson Agents Anti-Dyskinesia Agents Catechol O-Methyltransferase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Dopamine Agents Neurotransmitter Agents Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on September 30, 2016